Recorded December 14, 2007 at 12:30 PM
Joseph L. Kuti, PharmD,
Associate Director, Clinical and Economic Studies, Hartford Hospital Center for Anti-Infective Research and Development, Hartford, CT
This program is presented for educational purposes only and is no longer available for CME credit.
Disclosure: Dr. Kuti currently serves on the advisory boards/panels of AstraZeneca, Elan, and Pfizer; as a consultant to AstraZeneca, Elan, Pfizer, and Wyeth; receives grants/research support from AstraZeneca, Pfizer, and Wyeth; and serves on the speaker’s bureaus of AstraZeneca, Elan, Pfizer, Merck and Wyeth. He intends to discuss the increased dosages as well as varied infusion times for cefepime, imipenem, ciprofloxacin, levofloxacin, meropenem, piperacillin / tazobactam and fluoroquinolones in his presentation.
Clinical Content Reviewer: Juan Dumois, MD
Learning Objectives: As a result of attending this presentation, participants will be able to:
Commercial Support: No
While the presentations may be viewable on systems that don't meet these criteria, we recommend that you use a computer that meets the following standards:
|Pocket Doc Mobile App|
|Maps and Locations (Mobile)|
|Programs & Services|
|For Health Professionals|
|For Patients & Families|
|Find a Doctor|